Widespread use of maternal RSV vaccination and nirsevimab during the 2024–2025 U.S. RSV season led to a significant reduction ...

On the heels of a fall and winter that saw hundreds of Alberta babies and toddlers hospitalized and two young children die ...

RSV-NET data showed that RSV hospitalization rates among infants aged 0 to 7 months were an estimated 43% (95% confidence ...

Two preventive tools — a maternal vaccine and a monoclonal antibody — were tied to a recent drop in RSV hospitalization rates for U.S. babies.

Nirsevimab is effective for reducing the burden of respiratory syncytial virus (RSV) in infants in real-world settings.

Maternal RSV vaccination and nirsevimab were associated with a reduction in hospitalization rates among infants aged 0 to 7 months.

New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the ...

Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated ...

Bulletin: ...FLASH FLOOD WARNING REMAINS IN EFFECT UNTIL 415 PM EDT THIS AFTERNOON FOR NORTHWESTERN BURLINGTON, NORTH CENTRAL CAMDEN, SOUTHEASTERN BUCKS, EAST CENTRAL ...

Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated ...

The Centers for Disease Control and Prevention May 8 released an analysis that found declines in hospitalizations for infants infected with respiratory syncytial virus during the 2024-2025 RSV season.